Eli Lilly
2,485 hedge funds and large institutions have $257B invested in Eli Lilly in 2022 Q3 according to their latest regulatory filings, with 157 funds opening new positions, 942 increasing their positions, 936 reducing their positions, and 85 closing their positions.
85% more first-time investments, than exits
New positions opened: 157 | Existing positions closed: 85
3% more funds holding in top 10
Funds holding in top 10: 183 → 188 (+5)
2% more funds holding
Funds holding: 2,446 → 2,485 (+39)
1% more capital invested
Capital invested by funds: $255B → $257B (+$2.12B)
0.74% more ownership
Funds ownership: 82.96% → 83.71% (+0.74%)
1% more repeat investments, than reductions
Existing positions increased: 942 | Existing positions reduced: 936
5% less call options, than puts
Call options by funds: $2.43B | Put options by funds: $2.55B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.4B |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$1.11B |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$586M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$424M |
| 5 |
Amundi
Paris,
France
|
+$367M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$644M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$505M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$431M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$344M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$310M |
LLY Hedge Fund Activity: Q3 2022 in Review
2,485 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q3 2022, worth a combined $257B — up 0.83% from $255B a quarter earlier.
Buyers outnumbered sellers: 157 funds opened new LLY positions and 85 closed out — a net gain of 72 holders — while 942 added to existing stakes and 936 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $1.4B. The largest seller was Fisher Asset Management, cutting an estimated $644M.
- 2,485 institutional investors held Eli Lilly (LLY) as of Q3 2022, up from 2,446 in Q2 2022.
- Funds reported $257B of Eli Lilly stock for Q3 2022, up 0.83% quarter-over-quarter.
- 157 funds opened new Eli Lilly positions in Q3 2022 and 85 closed out, a net change of +72 holders.
- The largest Eli Lilly buyer in Q3 2022 was T. Rowe Price Associates, an estimated $1.4B added.
- The largest Eli Lilly seller in Q3 2022 was Fisher Asset Management, an estimated $644M sold.
Based on aggregated 13F filings for Q3 2022.